Harmony Biosciences Holdings (HRMY)

Return on equity (ROE)

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020
Net income (ttm)	US$ in thousands	128,853	150,755	200,237	189,468	181,468	155,673	58,110	48,696	34,597	11,675	23,204
Total stockholders’ equity	US$ in thousands	466,992	481,332	485,172	443,041	402,838	343,884	246,533	214,503	186,507	152,018	126,551	107,879	97,180	94,549
ROE		27.59%	31.32%	41.27%	42.77%	45.05%	45.27%	23.57%	22.70%	18.55%	7.68%	18.34%

December 31, 2023 calculation

ROE = Net income (ttm) ÷ Total stockholders’ equity
= $128,853K ÷ $466,992K
= 27.59%

The return on equity (ROE) of Harmony Biosciences Holdings Inc has shown some fluctuations over the past eight quarters. ROE measures the company's ability to generate profit from shareholders' equity.

In Q4 2022, the ROE was at a relatively high level of 45.05%, but it slightly decreased in the following quarter to 45.27%. Subsequently, there was a significant drop in the ROE in Q2 2022 to 23.57%, which rebounded in Q3 2022 to 22.70%.

The company's ROE then experienced a notable upturn in Q1 2023 to 42.77%, and this positive trend continued in Q2 2023 and Q3 2023, reaching 41.27% and 31.32% respectively. However, there was a decline in Q4 2023 to 27.59%.

Overall, Harmony Biosciences Holdings Inc has demonstrated variable ROE performance over the analyzed period, with fluctuations in profitability relative to shareholders' equity. These changes could be influenced by various factors such as revenue growth, cost management, and capital structure. Further analysis and context would be necessary to fully understand the drivers behind these fluctuations.